To further promote the development of the company's main business and enhance the company's competitiveness, Zhejiang Hichi Pharmaceutical Co., Ltd., its holding subsidiary, launched a new ...
Recently, Beilu Pharmaceutical Jiuwei Zhenxin Granules were successfully selected into the "Science and Innovation China" New Drug Achievement Case Library of the China Association for Scien...
Non ionic contrast medium is the second generation of CT contrast medium. Compared with the first generation of ionic contrast medium, the non ionic contrast medium has greater water solubility. In ad...
Recently, the Beijing Municipal Federation of Industry and Commerce and the Beijing Branch of China Construction Bank jointly held the“2021 Beijing Top 100 Private Enterprises Press Conference”.
Recently, our company received the“Drug Supplementary Application Approval Notice”(Notice Number: 2021B02267, 2021B02268) for two specifications of Gadopentetate Dimeglumine Injection.
Beilu Pharma participated in the fifth round of national centralized drug procurement organized by the National Organization for Centralized Drug Procurement and Use of the Joint Procurement Office.
Beijing Beilu Pharmaceutical Co., Ltd received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration (NMPA) on Iodixanol Injection.